Don and Marilyn Anderson<br />Professor in Oncology<br /> Associate Dean for Therapeutics Development <br /> University of Wisconsin School of<br />Medicine and Public Health<br /> University of Wisconsin in Madison<br /> USA
Dr. Jacques Galipeau
Topic: Development of a Living Cell Pharmaceutical – the Mesenchymal Stromal Cell Paradigm
Jacques Galipeau, MD obtained his Medical Degree from the University of Montreal and completed specialty training in internal medicine at McGill University. He went on to the Tufts-affiliated New England Medical Center in Boston for three years of subspecialty training in Hematology & Medical Oncology followed by a two-year scientific fellowship in gene therapy at St-Jude Children’s research hospital in Memphis, Tennessee. Dr. Galipeau served as Hematology and Oncology Faculty at McGill University (1997-2009) and Tenured Professor and Georgia Cancer Coalition Distinguished Cancer Scholar at Emory University (2009-2016). Since 2016, he has been the Don and Marilyn Anderson Tenured Professor of Oncology within the Department of Medicine and UW Carbone Comprehensive Cancer Center at the University of Wisconsin in Madison and was appointed the inaugural Associate Dean for Therapeutics Development at the UW School of Medicine and Public Health.
Dr. Galipeau is an academic health center biopharmaceutical leader with broad experience leading groups responsible for discovery research, GMP compliant cell manufacture, clinical trial design, FDA regulatory approval of clinical trials within academia and execution spanning pre-clinical to first-in-human studies across multiple therapeutic areas. Specific focus on team building within university and healthcare enterprises to enable bridging to clinical development and strategic decision-making to optimize speed and impact of programs emerging from basic university research discoveries to cost effective and impactful health care living therapeutics deployment permissive for marketing approval.
He is the founding director of the University of Wisconsin Program for Advanced Cell Therapy (PACT). The mission of this program is to develop personalized cell therapies for immune and malignant disorders and to promote and deploy first-in-human clinical trials of UW-Madison cell therapy innovations to improve outcomes for children and adults. He is a practicing hematologist and internationally recognized expert in discovery science and translational development of mesenchymal stromal cell therapies. Innovator in the field of engineered synthetic cytokines as novel pharmaceutical means of treating immune disorders such as colitis, multiple sclerosis and cancer.
Dr Galipeau is President (2022-2024) of the International Society of Cell Therapy.